Reply letter: Pathologic complete response in TNBC: A shield against recurrence, but not the brain?

Ítems similars

• Reply letter: Pathologic complete response in TNBC: A shield against recurrence, but not the brain?
  per: Gabriel Berlingieri Polho, et al.
  Publicat: (2025-12-01)
• Development and validation of a nomogram for predicting rapid relapse in triple-negative breast cancer patients treated with neoadjuvant chemotherapy
  per: Tao Ma, et al.
  Publicat: (2024-09-01)
• Evaluation of weekly paclitaxel plus carboplatin followed by anthracycline chemotherapy on the neoadjuvant treatment of patients with triple-negative breast cancer
  per: Aurelio B. Castrellon, et al.
  Publicat: (2018-01-01)
• Real-world outcome of neoadjuvant therapy with or without pembrolizumab for triple-negative breast cancer
  per: Johanna Mattson, et al.
  Publicat: (2026-02-01)
• Efficacy and safety of Anlotinib based neoadjuvant chemotherapy for locally advanced triple negative breast cancer (TNBC)
  per: Kuojun Ren, et al.
  Publicat: (2024-10-01)